Literature DB >> 6313952

The active site of lysosomal sphingomyelinase: evidence for the involvement of hydrophobic and ionic groups.

J W Callahan, C S Jones, D J Davidson, P Shankaran.   

Abstract

The natural substrate for sphingomyelinase contains hydrophobic and polar moieties. In this study, we have employed pH rate studies and examined hydrophobic compounds and phosphorylated esters for their effect on sphingomyelinase activity in an attempt to determine some of the kinetic properties of this enzyme. Sphingomyelinase, purified from human placentae, undergoes noncompetitive inhibition by octylglucoside and Nonidet P-40, two nonionic detergents containing terminal octyl groups. The effect of these detergents at the hydrophobic binding site is somewhat different from that of Triton X-100, which contains an isooctyl terminal group, and this may serve to identify a structural basis for the effects. Sphingomyelinase activity is also modulated by several nucleotides. Inhibition by 5'-adenosine monophosphate (5'-AMP) is also noncompetitive. Other nucleotide monophosphates (such as 5'-uridine monophosphate (5'-UMP), 5'-cytidine monophosphate (5'-CMP), 2'-adenosine monophosphate (2'-AMP), and 3'-adenosine monophosphate (3'-AMP) and phosphorylated intermediates (such as phosphorylcholine, phosphorylethanolamine and hexose phosphates) have a lower inhibitory effect. The data suggest that the inhibition by 5'-AMP involves the combined effect of the phosphate group and the purine ring, structural requirements which may also be satisfied by bis(4-methylumbelliferyl)phosphate, a synthetic enzyme substrate. Studies of pH rate indicate that the maximal velocity for the hydrolysis of sphingomyelin is independent of pH over the range 3.5-6.2 while the Km value shows a pH dependence. The Km value is lowest from pH 4.0-5.2 and rises at pH values outside this range. The log Vmax/Km and pKm relationships, when plotted as a function of pH, have been used to identify the dissociation constants for the binding of sphingomyelin by the enzyme. These occur at pK values of 4.1 and 5.5. The activity of sphingomyelinase is also reduced when the enzyme is photooxidized in the presence of methylene blue or rose bengal and carbamylated by diethylpyrocarbonate (DEPC). These results are interpreted to show that 1). the enzyme contains a hydrophobic binding site which involves linear aliphatic moieties containing at least eight carbon atoms; 2) two ionic groups are involved in formation of the enzyme substrate complex, one of which is presumed to be the carboxylate group of aspartate or glutamate (represented by pK 4.1) and the second may be the protonated imidazolium group of histidine (represented by pK 5.5); and 3) since the maximal velocity shows no pH dependence, the interactions involving the hydrophobic and ionic groups affect only the binding of the substrate to the enzyme and formation of the enzyme-substrate complex.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313952     DOI: 10.1002/jnr.490100205

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  11 in total

Review 1.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

2.  Regulated secretion of acid sphingomyelinase: implications for selectivity of ceramide formation.

Authors:  Russell W Jenkins; Daniel Canals; Jolanta Idkowiak-Baldys; Fabio Simbari; Patrick Roddy; David M Perry; Kazuyuki Kitatani; Chiara Luberto; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2010-08-31       Impact factor: 5.157

3.  A model of the acid sphingomyelinase phosphoesterase domain based on its remote structural homolog purple acid phosphatase.

Authors:  Marian Seto; Marc Whitlow; Margaret A McCarrick; Subha Srinivasan; Ying Zhu; Rene Pagila; Robert Mintzer; David Light; Anthony Johns; Janet A Meurer-Ogden
Journal:  Protein Sci       Date:  2004-12       Impact factor: 6.725

Review 4.  Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Authors:  Russell W Jenkins; Daniel Canals; Yusuf A Hannun
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

Review 5.  Sphingomyelin metabolism at the plasma membrane: implications for bioactive sphingolipids.

Authors:  Delphine Milhas; Christopher J Clarke; Yusuf A Hannun
Journal:  FEBS Lett       Date:  2009-10-24       Impact factor: 4.124

6.  Sphingomyelinase treatment induces ATP-independent endocytosis.

Authors:  X Zha; L M Pierini; P L Leopold; P J Skiba; I Tabas; F R Maxfield
Journal:  J Cell Biol       Date:  1998-01-12       Impact factor: 10.539

7.  Human acid sphingomyelinase structures provide insight to molecular basis of Niemann-Pick disease.

Authors:  Yan-Feng Zhou; Matthew C Metcalf; Scott C Garman; Tim Edmunds; Huawei Qiu; Ronnie R Wei
Journal:  Nat Commun       Date:  2016-10-11       Impact factor: 14.919

8.  Ceramide activation of RhoA/Rho kinase impairs actin polymerization during aggregated LDL catabolism.

Authors:  Rajesh K Singh; Abigail S Haka; Alexandria Brumfield; Inna Grosheva; Priya Bhardwaj; Harvey F Chin; Yuquan Xiong; Timothy Hla; Frederick R Maxfield
Journal:  J Lipid Res       Date:  2017-08-16       Impact factor: 5.922

9.  Avicin G is a potent sphingomyelinase inhibitor and blocks oncogenic K- and H-Ras signaling.

Authors:  Christian M Garrido; Karen M Henkels; Kristen M Rehl; Hong Liang; Yong Zhou; Jordan U Gutterman; Kwang-Jin Cho
Journal:  Sci Rep       Date:  2020-06-04       Impact factor: 4.379

10.  Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis.

Authors:  Aaron I Gardner; Iram J Haq; A John Simpson; Katrin A Becker; John Gallagher; Vinciane Saint-Criq; Bernard Verdon; Emily Mavin; Alexandra Trigg; Michael A Gray; Albert Koulman; Melissa J McDonnell; Andrew J Fisher; Elizabeth L Kramer; John P Clancy; Christopher Ward; Edward H Schuchman; Erich Gulbins; Malcolm Brodlie
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.